Clinical Relevance of the Reverse Lipopolysaccharide Transport Pathway in Patients With Acute Peritonitis
LIPS
1 other identifier
observational
27
1 country
1
Brief Summary
When there is infection in the intra-abdominal area, bacteria secrete toxins that are absorbed by the peritoneum. These toxins then bind to lipoproteins (which carry cholesterol in the blood) and are eliminated by the liver. Phospholipid transfer protein (PLTP) is a protein that facilitates the binding of bacterial toxins to lipoproteins and thus their elimination. The objective of this study is to study the relationship between PLTP and the elimination of bacterial toxins in humans. A better understanding of the elimination of these toxins will lead to a better understanding of the disease. The ultimate objective is to improve the management of intra-abdominal infections.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Dec 2019
Typical duration for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 11, 2019
CompletedFirst Posted
Study publicly available on registry
October 15, 2019
CompletedStudy Start
First participant enrolled
December 19, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 27, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
October 27, 2022
CompletedAugust 29, 2023
August 1, 2023
2.9 years
October 11, 2019
August 28, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Perioperative plasma concentration in 3HM
24 hours postoperatively
Study Arms (1)
Patients with suspected peritonitis
Secondary peritonitis, sepsis and endotoxemia
Interventions
4 blood samples of 6 ml each: one before the surgical incision, one after the operation, one 4h after the operation and the last 24h after the operation.
Eligibility Criteria
patients with secondary peritonitis, sepsis and endotoxemia
You may qualify if:
- person who has given oral consent (patient or family member)
- pre-operative SEPSIS criteria (qSOFA \>=2) or vasopressor or mechanical ventilation treatment
- admitted to the operating room for suspected generalized secondary peritonitis
You may not qualify if:
- person not affiliated to national health insurance
- person under legal protection (curatorship, guardianship)
- person under court order
- pregnant, parturient or breastfeeding woman
- minor
- immunosuppression (HIV infection, corticosteroid treatment \> 0.15 mg/kg/day prednisolone equivalent \> 2 weeks, immunosuppressive treatment, primary cellular immune deficiency)
- decision to limit or stop therapy
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Chu Dijon Bourogne
Dijon, 21000, France
Related Publications (1)
Nguyen M, Alvarez M, Berthoud V, Pallot G, Abagri S, Leleu D, Pais-De-Barros JP, Ortega-Deballon P, Guinot PG, Masson D, Gautier T, Bouhemad B. High-density lipoproteins alleviate the endotoxin burden in patients with peritonitis and sepsis: The LIPS study. Eur J Clin Invest. 2025 Dec;55(12):e70099. doi: 10.1111/eci.70099. Epub 2025 Jul 19.
PMID: 40682387DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 11, 2019
First Posted
October 15, 2019
Study Start
December 19, 2019
Primary Completion
October 27, 2022
Study Completion
October 27, 2022
Last Updated
August 29, 2023
Record last verified: 2023-08